MEDP · Medpace Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $706.60M | - | $659.90M | $603.31M | $558.57M | - | $533.32M | $528.10M | $511.04M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $47.92M | - | $48.08M | $46.66M | $57.90M | - | $49.22M | $41.45M | $44.08M | - |
| Total Operating Expenses | $565.10M | - | $518.10M | $476.98M | $445.05M | - | $421.04M | $422.95M | $406.98M | - |
| D&A | $6.75M | - | $6.81M | $6.78M | $6.69M | - | $7.16M | $6.87M | $6.63M | - |
| Operating Income | $141.50M | - | $141.81M | $126.33M | $113.52M | - | $112.27M | $105.15M | $104.07M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $23.72M | - | $31.70M | $34.28M | $3.58M | - | $22.35M | $22.13M | $10.19M | - |
| Net Income | $123.87M | - | $111.14M | $90.26M | $114.59M | - | $96.43M | $88.35M | $102.59M | - |
| EPS - Basic | $4.35 | - | $3.95 | $3.16 | $3.77 | - | $3.11 | $2.85 | $3.32 | - |
| EPS - Diluted | $4.28 | - | $3.86 | $3.10 | $3.67 | - | $3.01 | $2.75 | $3.20 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $652.68M | $497.05M | $285.35M | $46.33M | $441.44M | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M |
| Accounts Receivable | $394.58M | $402.08M | $373.03M | $377.92M | $298.22M | $296.44M | $311.47M | $301.11M | $279.17M | $298.40M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $34.43M | $28.14M | $26.52M | $43.27M | $61.32M | $32.53M | $26.20M | $27.39M | $24.40M | $31.87M |
| Current Assets | $1.14B | $989.62M | $737.28M | $520.80M | $821.44M | $1.03B | $1.03B | $872.52M | $744.90M | $593.83M |
| Total Assets | $2.13B | $1.98B | $1.75B | $1.57B | $1.90B | $2.10B | $2.08B | $1.92B | $1.80B | $1.66B |
| Current Liabilities | $1.35B | $1.34B | $1.28B | $1.22B | $1.12B | $1.10B | $1.04B | $993.09M | $956.64M | $925.13M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.53B | $1.52B | $1.46B | $1.40B | $1.30B | $1.28B | $1.20B | $1.16B | $1.12B | $1.10B |
| Stockholders' Equity | $598.31M | $459.07M | $293.64M | $172.35M | $593.61M | $825.54M | $881.44M | $763.60M | $671.54M | $558.95M |
| Retained Earnings | ($336.11M) | ($459.98M) | ($596.24M) | ($703.22M) | ($269.72M) | $8.17M | $65.64M | ($30.79M) | ($119.14M) | ($221.65M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $151.79M | - | - | - | $125.84M | - | - | - | $152.68M | - |
| Investing Cash Flow | ($6.75M) | - | - | - | ($9.99M) | - | - | - | $2.53M | - |
| Financing Cash Flow | $12.67M | - | - | - | ($345.97M) | - | - | - | $7.66M | - |
| CapEx | $6.81M | - | - | - | $9.99M | - | - | - | $5.50M | - |
| Free Cash Flow | $144.97M | - | - | - | $115.84M | - | - | - | $147.18M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 20.0% | - | 21.5% | 20.9% | 20.3% | - | 21.1% | 19.9% | 20.4% | - |
| EBITDA margin | 21.0% | - | 22.5% | 22.1% | 21.5% | - | 22.4% | 21.2% | 21.7% | - |
| Net margin | 17.5% | - | 16.8% | 15.0% | 20.5% | - | 18.1% | 16.7% | 20.1% | - |
| Free cash flow margin | 20.5% | - | - | - | 20.7% | - | - | - | 28.8% | - |
| FCF / Net income | 1.17 | - | - | - | 1.01 | - | - | - | 1.43 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 6.8% | - | 7.3% | 7.7% | 10.4% | - | 9.2% | 7.8% | 8.6% | - |
| Effective tax rate | 16.1% | - | 22.2% | 27.5% | 3.0% | - | 18.8% | 20.0% | 9.0% | - |
| Return on assets | 5.8% | - | 6.3% | 5.7% | 6.0% | - | 4.6% | 4.6% | 5.7% | - |
| Return on equity | 20.7% | - | 37.8% | 52.4% | 19.3% | - | 10.9% | 11.6% | 15.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.85 | 0.74 | 0.57 | 0.43 | 0.73 | 0.93 | 0.99 | 0.88 | 0.78 | 0.64 |
| Quick ratio | 0.85 | 0.74 | 0.57 | 0.43 | 0.73 | 0.93 | 0.99 | 0.88 | 0.78 | 0.64 |
| Cash ratio | 0.49 | 0.37 | 0.22 | 0.04 | 0.39 | 0.61 | 0.63 | 0.51 | 0.43 | 0.27 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.56 | 4.30 | 5.97 | 9.12 | 3.20 | 2.54 | 2.36 | 2.51 | 2.67 | 2.96 |
| Liabilities / Assets | 0.72 | 0.77 | 0.83 | 0.89 | 0.69 | 0.61 | 0.58 | 0.60 | 0.63 | 0.66 |
| Efficiency | ||||||||||
| Asset turnover | 0.33 | - | 0.38 | 0.38 | 0.29 | - | 0.26 | 0.28 | 0.28 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 204d | - | 206d | 229d | 195d | - | 213d | 208d | 199d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 112.2x | - | 133.2x | 101.2x | 83.0x | - | 110.9x | 149.8x | 126.3x | - |
| P / B | 23.2x | - | 50.5x | 53.1x | 16.0x | - | 12.2x | 17.3x | 19.3x | - |
| P / S | 19.7x | - | 22.5x | 15.2x | 17.0x | - | 20.1x | 25.0x | 25.3x | - |
| EV / EBITDA | 89.4x | - | 97.8x | 68.4x | 75.4x | - | 84.2x | 113.4x | 113.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 26.5% | - | 23.7% | 14.2% | 9.3% | - | 8.3% | 14.6% | 17.7% | - |
| Revenue CAGR (3y) | 17.6% | - | 19.8% | 19.8% | 19.1% | - | 21.7% | 23.8% | 25.3% | - |
| Revenue CAGR (5y) | 22.1% | - | 23.4% | 24.1% | 19.3% | - | 19.8% | 19.8% | 20.5% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 24.6% | - | 26.3% | 20.1% | 9.1% | - | 32.2% | 34.1% | 20.7% | - |
| Net income growth (YoY) | 8.1% | - | 15.3% | 2.2% | 11.7% | - | 36.7% | 44.7% | 40.7% | - |
| EPS growth (YoY) | 16.6% | - | 28.2% | 12.7% | 14.7% | - | 35.6% | 42.5% | 41.0% | - |
| EPS CAGR (3y) | 23.5% | - | 23.5% | 28.5% | 29.5% | - | 32.6% | 37.4% | 41.1% | - |
| EPS CAGR (5y) | 30.3% | - | 28.8% | 37.1% | 37.0% | - | 36.7% | 30.4% | 44.4% | - |
| FCF growth (YoY) | 25.1% | - | - | - | -21.3% | - | - | - | 108.6% | - |
| FCF CAGR (5y) | 23.3% | - | - | - | 21.6% | - | - | - | 47.9% | - |
| Book value growth (YoY) | 0.8% | -44.4% | -66.7% | -77.4% | -11.6% | 47.7% | 87.2% | 95.3% | 93.4% | 44.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.53B totalReportable Segment$2.53B · 100.0%
Product / service
$2.53B totalOncology$747.59M · 29.5%
Metabolic$744.96M · 29.4%
Other$408.55M · 16.1%
Central Nervous System$254.84M · 10.1%
Cardiology$239.37M · 9.5%
Antiviral And Anti Infective$134.94M · 5.3%
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing Medpace Holdings against the 5 most active filers in the same SIC group.